Renalytix PLC
LSE:RENX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (0.3), the stock would be worth GBX-0.85 (147% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.6 | GBX1.8 |
0%
|
| Industry Average | 0.3 | GBX-0.85 |
-147%
|
| Country Average | 0.2 | GBX-0.62 |
-134%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
Renalytix PLC
LSE:RENX
|
7.9m GBP | -0.6 | -0.5 | |
| JP |
|
Medical Data Vision Co Ltd
TSE:3902
|
37.9T JPY | 88.6 | 227.5 | |
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD | 36.2 | 53.1 | |
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
28.1B USD | 20.3 | 30.9 | |
| AU |
|
Pro Medicus Ltd
ASX:PME
|
14.2B AUD | 119.4 | 60.6 | |
| JP |
|
M3 Inc
TSE:2413
|
1T JPY | 23.5 | 20.5 | |
| SE |
|
Sectra AB
STO:SECT B
|
49.2B SEK | 79.2 | 91.5 | |
| US |
|
Doximity Inc
NYSE:DOCS
|
4.6B USD | 15.1 | 19.3 | |
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
4B USD | 8.6 | 35 | |
| IN |
I
|
Inventurus Knowledge Solutions Ltd
NSE:IKS
|
283.9B INR | -201.6 | 42.8 | |
| CN |
|
Winning Health Technology Group Co Ltd
SZSE:300253
|
19.1B CNY | 80 | -62.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.1 |
| Median | 0.2 |
| 70th Percentile | 0.4 |
| Max | 901.8 |
Other Multiples
Renalytix PLC
Glance View
Renalytix Plc manufactures medical devices and equipment. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2018-11-06. The firm is focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. The firm's diagnostic platform, KidneyIntelX, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The firm is evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and coronavirus disease (COVID)-related kidney disease. KidneyIntelX platform facilitates the identification and promotes the effective management of patients at risk of early-stage diabetic kidney disease (DKD), progression by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record (HER) using a proprietary algorithm to generate a unique patient risk score.
